Treatment of mycosis fungoides with topical nitrosourea compounds: Further studies.
Twenty-six patients with mycosis fungoides were treated topically with three nitrosourea compounds: carmustine (BCNU), lomustine (CCNU), and 1-methyl-1-nitrosourea. A high percentage experienced good to excellent results. Remissions following treatment of individual lesions varied from one month to at least three years. Remissions following total body surface treatment varied from two weeks to at least four months. Two of 13 patients treated over the entire body suffered temporary bone marrow depression, indluding one with severe pancytopenia. This toxic effect was attributed to lomustine and was not seen in patients treated with carmustine alone. Thirteen patients highly allergic to mechlorethamine hydrochloride showed no cross-sensitivity to nitrosourea compounds. A primary irritant dermatitis occurred in about one half of the patients and telangiectasia in two. Two patients developed hypersensitivity to nitrosourea compounds. Carmustine is the preferred nitrosourea compound for topical therapy of mycosis fungoides.
D000287:Administration, Topical; D000328:Adult; D000368:Aged; D001853:Bone Marrow / Q000187:drug effects; D002330:Carmustine / Q000627:therapeutic use; D003429:Cross Reactions; D004342:Drug Hypersensitivity / Q000209:etiology; D005260:Female; D006801:Humans; D008130:Lomustine / Q000627:therapeutic use; D008297:Male; D008466:Mechlorethamine / Q000009:adverse effects; D008770:Methylnitrosourea / Q000627:therapeutic use; D008875:Middle Aged; D009182:Mycosis Fungoides / Q000188:drug therapy* / Q000473:pathology; D009607:Nitrosourea Compounds / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000473:pathology
D009607:Nitrosourea Compounds; D008466:Mechlorethamine; D008770:Methylnitrosourea; D008130:Lomustine; D002330:Carmustine